오존, 오존과산화수소와 오존활성탄 처리에 의한 페놀 및 그 부산물의 제거에 관한 연구

학위논문(석사)--서울大學校 保健大學院 :環境保健學科 環境衛生學專攻,1997.Maste

Atypical Presentation of Pneumocystis jirovecii Infection in HIV Infected Patients: Three Different Manifestations

Advances in the treatment and prevention of Pneumocystis jirovecii infection (PJI) in human immunodeficiency virus (HIV) patients decreased incidence and mortality dramatically, however, it may be associated with an increased frequency of unusual manifestation such as cystic formation, pneumothorax, focal infiltration, nodular formation, or extrapulmonary lesions. We report three cases of PJI with atypical manifestations. Each case demonstrates different clinical features: multiple nodular pulmonary lesion (32-year-old man with abnormal chest X-ray finding), subpleural mass-like lesion (43-year-old man with left visual loss and right pleuritic chest pain), and extrapulmonary mass-like lesions in the liver, lymph nodes, and small bowel (39-year-old man with cough, sputum, and dyspnea). P. jirovecii was confirmed in all 3 cases and they were treated well. It is necessary to understand that PJI shows variable clinical features

Predictors of mortality in Middle East respiratory syndrome (MERS)

We evaluated the clinical characteristics, cytokine/chemokine concentrations, viral shedding and antibody kinetics in 30 patients with Middle East respiratory syndrome (MERS), including 6 non-survivors admitted to 3 MERS-designated hospitals. Old age, low albumin, altered mentality and high pneumonia severity index score at admission were risk factors for mortality. In addition, severe signs of inflammation at initial presentation (at hospital days 1-4), such as high inducible protein-10 (p=0.0013), monocyte chemoattractant protein-1 (p=0.0007) and interleukin 6 (p=0.0007) concentrations, and poor viral control (high viral load at hospital days 5-10, p<0.001) without adequate antibody titres (low antibody titre at hospital days 11-16, p=0.07) during the course of disease, were associated with mortality.This study was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C2774, HI15C2859 and HI15C2888), from the National Research Foundation, funded by the Ministry of Science, ICT and Future Planning, Republic of Korea (NRF-2015R1A4A1042416), and from the Asan Institute for Life Sciences (Grant No. 2016-462). It was also supported by the Korean Society for Chemotherapy

Development of Heavy Metal Resistant Plants by Expression of ZntA from E. coli

Maste

위암 세포주에서 CDK4/6 inhibitor의 감수성 평가와 biomarker 탐색

Gastric cancer (GC) is the fourth most common cancer and second leading cause of cancer mortality worldwide. The median survival of patients with metastatic gastric cancer has a poor prognosis, less than 2 years. Recent development of molecular biological research suggests trastuzumab and ramucirumab as targeted therapies for GC. However, there are limitations that only 10% of GC patients are HER2-positive for trastuzumab therapy, and that identified ramucirumab biomarker is scarce emphasizing the need to find novel targeted agents to improve outcomes. Recently, therapeutics targeting CDK that regulate the cell cycle have been developed and clinical trials are undergoing in various cancers, especially those investigating the G1 phase arrest induced by CDK4 and CDK6 inhibitions. CDK4/6 inhibitors have demonstrated tumor growth suppression in several PDX models, including non-small cell lung cancer (NSCLC), melanoma, and glioblastoma; however, their efficacy in gastric cancer is not sufficiently supported. In this study, we investigated the anti-proliferative effect of abemaciclib in gastric cancer and conducted the search for a biomarker that can predict its response. We profiled G1/S related genetic and molecular characteristics in 49 gastric cancer cell lines and pinpointed the factors associated with abemaciclib sensitivity with augmented focus on the methylation of p16 gene. p16 methylation was the most prominent predictive marker of abemaciclib sensitivity, and change in abemaciclib response was observed when a decrease in methylation levels was induced. The anti-proliferative effect of abemaciclib, which induces G1 phase arrest and inhibits Rb phosphorylation, was confirmed in vitro and in vivo. Hence, we propose CDK4/6 inhibitors as promising targeted agents and the methylation of p16 as a predictive marker in gastric cancer. 위암은 전세계적으로 네번째로 높은 발병률을 나타내며 암 사망원인 3위이다. 전이성 위암환자의 중앙 생존기간은 2년 미만으로 좋지 않은 예후를 보인다. 최근 분자 생물학적인 연구와 기술의 개발로 맞춤치료의 일환으로 HER2 양성인 진행성 위암환자를 대상으로 HER2에 대한 단일클론 항체인 trastuzumab의 사용과 2차 치료 전략으로써 ramucirumab이 치료 옵션으로 권고된다. 그러나 HER2 양성 위암 환자는 10%에 불과하며 입증된 ramucirumab의 biomarker는 없다. 따라서 예후가 좋지 않고 유병률이 높은 진행성 위암 치료에 대한 새로운 접근 기법이 절실한 상황이다. 최근 세포주기를 조절하는 CDK를 표적으로 하는 치료제들이 개발되고 다양한 암 종에서 임상시험이 진행 중이다. 그 중 CDK4와 CDK6를 이중으로 억제하여 G1기의 arrest를 유도하는 억제제를 사용하는 많은 임상 연구가 진행 중이고 대표적으로 palbociclib (Pfizer), abemaciclib (Lilly), ribociclib (Novartis) 등이 있다. CDK4/6 inhibitor는 비소세포폐암 (NSCLC), 흑색종, 아교모세포종을 비롯한 여러 PDX 모델에서 종양 성장 억제 효과를 나타냈고 유방암, 흑색종을 대상으로 한 임상 1상 시험에서 효과를 보였지만 위암에서 CDK4/6 inhibitor를 대상으로 한 연구는 적은 상황이다. 본 연구에서는 위암에서 CDK4/6 inhibitor인 abemaciclib의 표적치료제로써의 효과를 확인하고, 약제의 효과를 예측할 수 있는 biomarker를 찾아보고자 한다. 49개 위암세포주에서 G1/S기 관련 인자의 유전적 변이와 발현을 확인하고 abemaciclib 감수성과 관련 지어 효과를 나타내는 인자를 찾아본 결과 p16 유전자의 methylation이 abemaciclib 감수성과 연관이 있는 것을 확인하였고 이를 증명하기 위해 methylation 수준을 감소시켰을 때의 abemaciclib 감수성 변화를 확인했다. 또한 abemaciclib 감수성을 토대로 세포주를 선별한 뒤, 약제의 효능을 in vitro와 in vivo 상에서 확인하였다. 이로써 CDK4/6 억제제가 위암 치료에 있어 유망하며 p16의 methylation은 약제의 효과를 예측할 수 있는 predictive marker로 가능성이 있음을 제시하고자 한다.open석

기업의 재무제약.투자.현금보유에 관한 연구

학위논문(석사) --서울대학교 대학원 :경영학과(재무금융전공),2010.8.Maste

Sequence analysis and expression of the gene encoding the 56-kilodalton protein of Rickettsia tsutsugamushi TA686

학위논문(박사)--서울대학교 대학원 :의학과 미생물학전공,1996.Docto